Compare Cassava Sciences Inc (FLNA) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs SYSCO Corporation — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while SYSCO Corporation trades at $78.14 (market cap $38.47B). The key difference: SYSCO Corporation is far larger — about 976.4× Cassava Sciences Inc's market cap, and SYSCO Corporation pays a 2.81% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and SYSCO Corporation for 77 Days on average.
| FLNA | SYY | |
|---|---|---|
Market Cap | $39.40M | $38.47B |
Volume | 759,018 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $91.16 |
52-Week Low | $0.68 | $69.30 |
Typical Hold Time | 37 Days | 77 Days |
Enterprise Value | -$43.28M | $51.65B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Sysco (SYY) trades at $78.20, up 1.84% with neutral technical signals and strong institutional support. The stock shows solid fundamentals with $81.37B revenue, 2.08% net margin, and attractive valuation at P/E 21.37 and P/S 0.44. Recent corporate actions include a $0.55 dividend and $1B stock offering, while the company reaffirmed fiscal 2027 guidance and launched a $500M AI efficiency program.
Sysco presents a balanced investment case with 60% analyst buy ratings and $85.75 consensus target offering 9.6% upside. The food distribution leader benefits from consistent revenue growth and AI-driven efficiency initiatives, though margin pressure and competitive threats warrant monitoring. Current valuation appears reasonable given the company's market position and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
